FDA Approves First Alzheimer’s Drug in Decades

FDA just approved Lecanemab, the first drug to slow Alzheimer’s progression by targeting amyloid plaques—showing a 27% reduction in decline over 18 months for early-stage patients. It’s not a cure, but it offers real hope—and serious caution—with potential side effects like brain swelling requiring close monitoring. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bb0a0c60716bca7a